Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Vince Anzalone - VP, IR
Chris Anzalone - President and CEO
Bruce Given - Interim Chief Medical Scientist
Andy Davis - Senior Vice President and Head of Global Cardiometabolic Franchise
Ken Myszkowski - CFO
James Hamilton - Chief Discovery and Translational Medicine
Patrick O'Brien - COO and General Counsel
Conference Call Participants
Maury Raycroft - Jefferies
Ellie Merle - UBS
Luca Issi - RBC Capital
Edward Tenthoff - PSC
Jason Gerberry - Bank of America
CJ Yeh - Leerink Partners
Brendan Smith - TD Cowen
William Pickering - Bernstein
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Vince Anzalone
Thank you. And good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's Results for its Fiscal 2024 Third Quarter ended June 30 2024.
With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter; Dr. Bruce Given, Interim Chief Medical Scientist, who will provide an update on our cardiometabolic pipeline, Andy Davis, Senior Vice President and Head of Global cardiometabolic franchise, who will provide an update on commercial activities; and Ken Myszkowski, Chief Financial Officer, who will give a review of the financials. Dr. James Hamilton, Chief of Discovery and Translational Medicine; and Patrick O'Brien, COO and General Counsel, will also be available during the Q&A portion of the call.
Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q.
I'd now like to turn the call over to Chris Anzalone, President and CEO of the company. Chris?